ADHD Portfolio (Other)
Attention Deficit Hyperactivity Disorder (ADHD)
ApprovedMarketed
Key Facts
Indication
Attention Deficit Hyperactivity Disorder (ADHD)
Phase
Approved
Status
Marketed
Company
About Aytu BioScience
Aytu BioPharma is a publicly traded, commercial-stage biopharmaceutical company with a distinct focus on complex CNS conditions, including MDD and ADHD. Its strategy centers on acquiring, in-licensing, and commercializing novel therapeutics, supported by a best-in-class patient access platform, Aytu RxConnect. The company has built a portfolio of FDA-approved products, most notably the recently launched antidepressant EXXUA™ (gepirone), while managing a legacy portfolio of pediatric and other specialty products. Aytu's hybrid model generates revenue from commercial sales to fund operations and strategic growth initiatives.
View full company profileTherapeutic Areas
Other Attention Deficit Hyperactivity Disorder (ADHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AZSTARYS | Corium | Approved |
| Adzenys XR-ODT® | Aytu BioScience | Approved |
| Cotempla XR-ODT® | Aytu BioScience | Approved |